José A García-Marco1, Julio Delgado2, José A Hernández-Rivas3, Ángel Ramírez Payer4, Javier Loscertales Pueyo5, Isidro Jarque6, Pau Abrisqueta7, Pilar Giraldo8, Rafael Martínez9, Lucrecia Yáñez10, Mª José Terol11, Marcos González12, Francesc Bosch7. 1. Servicio de Hematología, Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, España. Electronic address: jagarciam@aehh.org. 2. Servicio de Hematología, Hospital Clínic i Provincial, Barcelona, España. 3. Servicio de Hematología, Hospital Universitario Infanta Leonor, Madrid, España. 4. Servicio de Hematología, Hospital Universitario Central de Asturias, Oviedo, Asturias, España. 5. Servicio de Hematología, Hospital Universitario de La Princesa, Madrid, España. 6. Servicio de Hematología, Hospital Universitario y Politécnico La Fe, Valencia, España. 7. Servicio de Hematología, Hospital Universitario Vall d'Hebron, Barcelona, España. 8. Servicio de Hematología, Hospital Universitario Miguel Servet, Zaragoza, España. 9. Servicio de Hematología, Hospital Clínico Universitario San Carlos, Madrid, España. 10. Servicio de Hematología, Hospital Universitario Marqués de Valdecilla, Santander, España. 11. Servicio de Hematología, Hospital Clínico Universitario, Valencia, España. 12. Servicio de Hematología, Hospital Clínico Universitario-Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, España.
Abstract
BACKGROUND AND OBJECTIVE: The broad therapeutic arsenal and the biological heterogeneity of patients with chronic lymphocytic leukemia (CLL) makes it difficult to standardize treatment for CLL patients with specific clinical settings in routine clinical practice. These considerations prompted us to elaborate the present consensus document, which constitutes an update of the previous version published in 2013, mainly focusing on novel treatment strategies that have been developed over last 5 years, namely B-cell receptor inhibitors (ibrutinib and idelalisib), anti-CD20 monoclonal antibodies (ofatumumab and obinutuzumab), and Bcl-2 inhibitors (venetoclax). MATERIAL AND METHODS: A group of experts from the Spanish Chronic Lymphocytic Leukemia Group reviewed all published literature from January 2010 to January 2016, in order to provide recommendations based on clinical evidence. For those areas without strong scientific evidence, the panel of experts established consensus criteria based on their clinical experience. RESULTS: The project has resulted in several practical recommendations that will facilitate the diagnosis, treatment, and follow-up of patients with CLL. CONCLUSIONS: There are many controversial issues in the management of CLL with no appropriate studies for making consensus recommendations.
BACKGROUND AND OBJECTIVE: The broad therapeutic arsenal and the biological heterogeneity of patients with chronic lymphocytic leukemia (CLL) makes it difficult to standardize treatment for CLL patients with specific clinical settings in routine clinical practice. These considerations prompted us to elaborate the present consensus document, which constitutes an update of the previous version published in 2013, mainly focusing on novel treatment strategies that have been developed over last 5 years, namely B-cell receptor inhibitors (ibrutinib and idelalisib), anti-CD20 monoclonal antibodies (ofatumumab and obinutuzumab), and Bcl-2 inhibitors (venetoclax). MATERIAL AND METHODS: A group of experts from the Spanish Chronic Lymphocytic Leukemia Group reviewed all published literature from January 2010 to January 2016, in order to provide recommendations based on clinical evidence. For those areas without strong scientific evidence, the panel of experts established consensus criteria based on their clinical experience. RESULTS: The project has resulted in several practical recommendations that will facilitate the diagnosis, treatment, and follow-up of patients with CLL. CONCLUSIONS: There are many controversial issues in the management of CLL with no appropriate studies for making consensus recommendations.
Authors: Ana Vagos Mata; Eduardo Espada; Daniela Alves; Blanca Polo; Maria João Costa; Conceição Lopes; João F Lacerda; João Raposo Journal: Cancer Med Date: 2021-11-16 Impact factor: 4.452
Authors: José María Bastida; María Teresa Cano-Mozo; Felix Lopez-Cadenas; Victor Eduardo Vallejo; Soraya Merchán; Cecilia Santos-Montón; David González-Calle; Javier Carrillo; Ana Africa Martín; Jose Angel Torres-Hernández; Marcos González; Francisco Martín-Herrero; Pedro Pabón; Jose Ramon González-Porras Journal: Medicine (Baltimore) Date: 2017-11 Impact factor: 1.817